

Title (en)
INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM

Title (de)
HEMMER DER ACETYL-COA-CARBOXYLASE ZUR BEHANDLUNG VON NEURONALEM HYPOMETABOLISMUS

Title (fr)
INHIBITEURS DE L'ACÉTYL-COA CARBOXYLASE POUR LE TRAITEMENT DE L'HYPOMÉTABOLISME NEURONAL

Publication
EP 2150265 A4 20100609 (EN)

Application
EP 08767785 A 20080514

Priority
• US 2008006352 W 20080514
• US 91788607 P 20070514

Abstract (en)
[origin: WO2008140828A1] This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others.

IPC 8 full level
A61K 38/00 (2006.01); **A61K 31/35** (2006.01); **A61P 25/28** (2006.01); **C07D 407/04** (2006.01); **C07K 7/06** (2006.01); **C12N 9/99** (2006.01)

CPC (source: EP US)
A61K 31/35 (2013.01 - EP US); **A61P 25/08** (2018.01 - EP); **A61P 25/14** (2018.01 - EP); **A61P 25/16** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **G01N 2800/52** (2013.01 - EP US)

Citation (search report)
• [XY] WO 03028631 A2 20030410 - ACCERA INC [US]
• [Y] WO 03063810 A2 20030807 - GILLETTE CO [US], et al
• [Y] US 6485941 B1 20021126 - WALDROP GROVER L [US], et al
• [Y] WO 03072197 A1 20030904 - PFIZER PROD INC [US], et al
• [XP] WO 2007115282 A2 20071011 - ACCERA INC [US], et al
• [AD] US 6835750 B1 20041228 - HENDERSON SAMUEL T [US]
• [AD] US 2002006959 A1 20020117 - HENDERSON SAMUEL T [US]
• [AD] WO 2004108740 A2 20041216 - US GOV HEALTH & HUMAN SERV [US], et al
• [Y] HARWOOD H JAMES JR ET AL: "Isozyme-nonspecific N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 39, 26 September 2003 (2003-09-26), pages 37099 - 37111, XP002580016, ISSN: 0021-9258
• [Y] YANG SHEN ET AL: "A Mechanism for the Potent Inhibition of Eukaryotic Acetyl-Coenzyme A Carboxylase by Soraphen A, a Macrocyclic Polyketide Natural Product", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US LNKD- DOI:10.1016/J.MOLCEL.2004.11.034, vol. 16, 22 December 2004 (2004-12-22), pages 881 - 891, XP007903549, ISSN: 1097-2765
• [Y] CRAMER CLAY T ET AL: "Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome.", JOURNAL OF LIPID RESEARCH JUL 2004 LNKD- PUBMED:15102884, vol. 45, no. 7, July 2004 (2004-07-01), pages 1289 - 1301, XP002580017, ISSN: 0022-2275
• [Y] OHMORI, KOICHI ET AL: "Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E", EUROPEAN JOURNAL OF PHARMACOLOGY, 471(1), 69-76 CODEN: EJPHAZ; ISSN: 0014-2999, 2003, XP002580018
• [Y] HENDERSON SAMUEL T: "High carbohydrate diets and Alzheimer's disease", MEDICAL HYPOTHESES, vol. 62, no. 5, 2004, pages 689 - 700, XP002580019, ISSN: 0306-9877

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2008140828 A1 20081120; AU 2008251742 A1 20081120; CA 2685380 A1 20081120; CN 101795701 A 20100804; EP 2150265 A1 20100210; EP 2150265 A4 20100609; JP 2010527360 A 20100812; US 2011003767 A1 20110106

DOCDB simple family (application)
US 2008006352 W 20080514; AU 2008251742 A 20080514; CA 2685380 A 20080514; CN 200880021598 A 20080514; EP 08767785 A 20080514; JP 2010508451 A 20080514; US 59947608 A 20080514